SNDX (Syndax Pharmaceuticals) Moat Score : 4/10 (As of Jul. 08, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Syndax Pharmaceuticals Moat Score?

Syndax Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Syndax Pharmaceuticals has Narrow Moat: Syndax Pharmaceuticals has a modest moat due to its valuable intellectual property and R&D capabilities. However, the competitive nature of the pharmaceutical industry and regulatory challenges limit its competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Syndax Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Competitive Comparison of Syndax Pharmaceuticals's Moat Score

For the Biotechnology subindustry, Syndax Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syndax Pharmaceuticals's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Moat Score falls into.

Save Embed

;

Save Embed

;

Syndax Pharmaceuticals (NAS:SNDX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Syndax Pharmaceuticals Moat Score Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

1T3:Germany

Address

730 Third Avenue, 9th Floor, New York, NY, USA, 10017

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Executives

Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Huber Martin H. Jr.	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Michael A Metzger	officer: President and COO	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Neil Gallagher	officer: President, Head of R&D	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Briggs Morrison	director, officer: Chief Executive Officer	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
William Meury	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Peter Ordentlich	officer: Chief Technology Officer	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Steve M Sabus	officer: Chief Commercial Officer	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Catherine Madigan	officer: Chief Medical Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Alexander Nolte	officer: Chief Accounting Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Fabrice Egros	director	C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Daphne Karydas	officer: Chief Financial Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451